Olokizumab

Olokizumab is a humanized monoclonal antibody designed for the treatment of Rheumatoid arthritis. It is developed by R-Pharm and UCB.

Mechanism of Action

Olokizumab works by targeting and inhibiting the IL-6 cytokine, a protein that plays an important role in the inflammatory response of the immune system. By blocking the action of IL-6, Olokizumab can reduce inflammation and slow the progression of rheumatoid arthritis.

Clinical Trials

Olokizumab has undergone Phase III clinical trials for the treatment of rheumatoid arthritis. The trials have shown that Olokizumab is effective in reducing the symptoms of rheumatoid arthritis and improving the quality of life for patients.

Side Effects

Like all medications, Olokizumab can cause side effects. The most common side effects reported in clinical trials include upper respiratory tract infections, nasopharyngitis, and injection site reactions.

Approval

Olokizumab has been approved for use in Russia and is currently under review by the EMA and the FDA in the United States.

See Also

• List of monoclonal antibodies
• Rheumatoid arthritis
• Interleukin 6

Olokizumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski